Hologic Inc Stock Price, News & Analysis

Hologic, a leader in women's health, announced a collaboration with Gallup to create the Hologic Global Women’s Health Index, the most extensive assessment of women’s health globally. This survey will encompass over 120,000 responses across 116 countries and will track vital metrics related to women’s health, including reproductive health and access to care. The project aims to address healthcare disparities exacerbated by the COVID-19 pandemic and will provide insights for policy improvement. The index is set to be published later this year.

Hologic, Inc. (Nasdaq: HOLX) has acquired Diagenode, a European developer of molecular diagnostic assays, for approximately $159 million. This acquisition aims to enhance Hologic's molecular diagnostics capabilities, speeding up international market entry and expanding their test menu. Diagenode brings over 30 real-time PCR tests for various infections and significant expertise in epigenetics. The acquisition is expected to be break-even to Hologic's non-GAAP earnings per share through fiscal 2022, with potential for future accretion.

Hologic, Inc. (NASDAQ: HOLX) has successfully completed its acquisition of Biotheranostics, a leader in molecular oncology, for approximately $230 million. Biotheranostics specializes in molecular diagnostic tests such as the Breast Cancer Index and CancerTYPE ID, which aid in predicting treatment benefits and optimizing therapy for patients with uncertain cancers. Following the acquisition, Hologic aims to grow in the expanding oncology market, leveraging the National Comprehensive Cancer Network's recent endorsement of Breast Cancer Index as a key predictive tool for hormone-receptor positive breast cancer.

A recent study published in the Journal of the American College of Radiology highlights significant racial disparities in breast cancer screening, particularly in digital breast tomosynthesis (DBT). The research, commissioned by Hologic (HOLX), analyzed data from over 385,000 women across various racial backgrounds and found that Black women were less likely to receive DBT mammograms, despite their higher mortality rate from breast cancer. Hologic is dedicated to addressing these disparities through partnerships and initiatives aimed at increasing access to advanced screening technologies for Black women.

AMETEK announced the appointment of Karleen Oberton to its Board of Directors, effective February 11, 2021. Oberton currently serves as CFO of Hologic and has over 30 years of experience in public accounting, biotechnology, and medical device manufacturing. Her expertise in finance and executive leadership is expected to enhance AMETEK's board dynamics. The company reported 2020 sales exceeding $4.5 billion and aims for double-digit growth in earnings per share over the business cycle.

Hologic, Inc. (Nasdaq: HOLX) will present at several upcoming virtual investor conferences, highlighting its commitment to women's health technology. Key events include:

• BTIG Virtual MedTech Conference on February 17 at 10:30 a.m. ET
• Citi’s Healthcare Services Conference on February 24 at 11:40 a.m. ET
• SVB Leerink’s Global Healthcare Conference on February 25 at 1:00 p.m. ET
• Raymond James Institutional Investors Conference on March 1 at 1:20 p.m. ET

All presentations will be webcast live and accessible on Hologic's investor website.

Hologic, Inc. (HOLX) has entered into a multi-year strategic collaboration with Google Cloud to integrate machine learning technologies with its Genius™ Digital Diagnostics System. This partnership aims to enhance cervical cancer screening by using AI for improved identification of pre-cancerous lesions and cancer cells. Hologic's President emphasized this as a natural progression in their 30-year commitment to cervical cancer screening. While the Genius system is CE-marked for the European market, it is not yet available in the U.S. Financial terms of the collaboration were not disclosed.